University Of Oklahoma
University Of Oklahoma (OU) is a public research university located in Norman, Oklahoma. Through its division University Of Oklahoma Univ Of Oklahoma Health Sciences Center Division, OU provides a wide range of goods and services to U.S. federal government agencies, primarily in the areas of medical research, healthcare, and education.
As a prime contractor, OU has provided radiopharmaceutical products, physician services, animal housing, research support services, and tuition reimbursement to federal agencies including the Departments of Veterans Affairs, Defense, Health and Human Services, Justice, and Navy. These goods and services were provided under firm fixed price, cost reimbursement, and time and materials contract types. Some contracts were set aside for small businesses. As a subcontractor, OU provided services including data analysis, specimen analysis, clinical trial support, drug development research, and subject matter expertise to prime contractors such as universities, medical centers, and research institutes.
Through prime and sub grants, OU has provided medical and scientific research, healthcare services, education and training programs, telemedicine capabilities, child trauma services, and other public health and human services. Major funding agencies have included the National Institutes of Health, Department of Agriculture, Department of Education, and Department of Justice. Subawards have been made to OU from universities, medical research foundations, cancer centers, and state health departments.
OU currently holds three indefinite delivery contracts from the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 19 for radiopharmaceuticals, animal housing, and ophthalmology services. Task orders issued against these contracts have supported the provision of routine radiopharmaceutical products, animal per diems, and physician services to VA medical centers in Oklahoma.
GY8NMUZQXVS7 611310
Not listed 865 Research Pkwy, Oklahoma City, OK 73104, USA
5/15/01 2/21/26 University Of Illinois
The University of Illinois, doing business as The Board of Trustees of the University of Illinois, is a major public research university system based in Chicago. As a comprehensive academic institution, it provides a wide range of educational services, research activities, and technical expertise to the federal government through numerous contract and grant awards. The university's capabilities span diverse fields including biomedical research, engineering, environmental studies, social sciences, and public health. With its extensive research facilities and accomplished faculty, the University of Illinois has established itself as a key partner for federal agencies seeking innovative solutions and cutting-edge research across multiple disciplines.
Through federal contracts, the University of Illinois has performed various research and development projects, technical services, and consulting work for agencies like the Department of Defense, National Institutes of Health, Department of Energy, and NASA. The university has served as both a prime contractor and subcontractor, often collaborating with industry partners, other academic institutions, and research organizations. Specific contract work has included drug development and testing, radiation dose response modeling, behavioral health assessments, animal research models, and advanced materials discovery. The contract awards have included both set-aside opportunities for small businesses and unrestricted competitions. For example, the university has conducted preclinical efficacy studies on cancer prevention agents for the National Cancer Institute and developed high-performance computing capabilities for Department of Energy laboratories.
On the federal grant side, the University of Illinois has received substantial funding from agencies like the National Institutes of Health, National Science Foundation, Department of Education, and Department of Health and Human Services. Its grant-funded activities span a diverse range of areas, including biomedical research, engineering, environmental studies, education, nursing, and social sciences. The university has undertaken projects related to cancer treatment, aging brain connectomics, environmental health disparities, STEM education initiatives, and minority health research. Often collaborating with other institutions, community organizations, and medical centers as both a prime grantee and sub-grantee, the University of Illinois has leveraged federal grant funding to advance scientific knowledge and address pressing societal challenges. For instance, it has led multi-site clinical trials on HIV prevention interventions and conducted longitudinal studies on child development with funding from NIH institutes.
The University of Illinois holds an Indefinite Delivery Indefinite Quantity (IDIQ) contract from the National Cancer Institute to support the PREVENT Cancer Preclinical Drug Development Program. This multiple-award contract, valued at $149,995,000, aims to provide a structured approach to the development of cancer drugs and vaccines from discovery through clinical trials. The contract includes three separate pools: evaluating the efficacy and biomarkers of cancer prevention regimens, preclinical product development and Good Manufacturing Practice manufacturing support for candidate cancer prevention vaccines, and assessing the pharmacological and toxicological effects of preventative agents. This IDIQ enables the university to compete for task orders to advance cancer prevention research and drug development efforts for the National Cancer Institute.
W8XEAJDKMXH3 611310
Not listed 809 S Marshfield Ave, Chicago, IL 60612, USA
5/14/02 12/19/25 IIT Research Institute
IIT Research Institute (IITRI) is a non-profit contract research organization and division of the Illinois Institute of Technology that specializes in preclinical drug development services for federal agencies. IITRI primarily supports the Department of Health and Human Services by conducting pharmacology, toxicology, safety, and efficacy evaluations of small molecule, biologic, and RNA therapeutic candidates across various disease areas to support Investigational New Drug (IND) applications. The organization leverages its expertise in non-GLP and GLP studies, analytical assay development, and process validation to advance promising therapies from discovery through clinical trials. IITRI has extensive experience providing these services to federal agencies through both prime contracts and subcontracts.
IITRI has been awarded numerous contracts from agencies such as the National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Neurological Disorders and Stroke (NINDS), and National Center for Advancing Translational Sciences (NCATS). These contracts have supported a wide range of preclinical research activities, including toxicology studies for cancer therapies, safety assessments of potential treatments for neurological disorders, and evaluation of vaccine candidates for infectious diseases. Notable projects include preclinical development of an RNA vaccine for prostate cancer prevention, non-clinical safety studies of compounds for conditions like neuropathic pain and acute cannabinoid overdose, and toxicology testing of COVID-19 related therapies. IITRI has also conducted subcontract work for other research institutions, performing specialized studies such as repeat dose toxicity evaluations of multivalent vaccines. The contracts awarded to IITRI are typically not associated with set-aside designations.
IITRI holds several significant indefinite delivery/indefinite quantity (IDIQ) contract vehicles with federal agencies. These include a $146.3 million single-award contract with NIAID for preclinical models of infectious diseases, a $48.6 million multiple-award contract with NCATS for safety evaluation and toxicology studies, and a $150 million multiple-award contract with NCI for the PREVENT Cancer Preclinical Drug Development Program. Additionally, IITRI has a $9.8 million single-award contract with NCI for preclinical toxicology of small molecule drugs and a $174.5 million single-award contract with NINDS for the Pharmacology and Toxicology for Therapeutics Program. These IDIQ vehicles enable federal agencies to efficiently access IITRI's comprehensive preclinical research capabilities on an as-needed basis, supporting critical drug development efforts across multiple therapeutic areas. Task orders under these IDVs have been awarded by various NIH institutes to conduct specific preclinical studies, ranging from toxicology assessments of cancer therapies to safety evaluations of neurological treatments.
DGBUFQYMKWB5 541715
Not listed 10 W 35th St #4, Chicago, IL 60616, USA
4/15/02 10/8/25 The Institute For Cancer Research
Here is a detailed four paragraph summary on The Institute For Cancer Research The Institute For Cancer Research Division:
The Institute For Cancer Research is a non-profit organization and subsidiary of Temple University that conducts biomedical research focused on cancer prevention, detection, diagnosis, and treatment. Through federal contract and grant awards, the entity provides a range of research, analytical, technical, and advisory services related to cancer biology, immunology, genetics, and clinical research.
The Institute For Cancer Research has provided various goods and services as a subcontractor to recipients of federal contracts. These include preclinical testing services for an influenza vaccine candidate for MRIGlobal and research services involving the analysis of plasma samples from cancer patients for the National Human Genome Research Institute. The Institute's federal contract work has been funded by agencies such as the Department of Health and Human Services and sets aside have generally not applied.
The Institute For Cancer Research has been awarded federal grants to study topics spanning immunotherapy, epigenetics, health disparities, and other areas of cancer research. As a prime grantee, the entity has received funding to test new approaches for cancer prevention and interception, examine residential history and prostate cancer outcomes, and develop text-based interventions to improve care, among other initiatives. Major funding agencies have included the National Institutes of Health, the Department of Defense, and the National Science Foundation. The Institute has also participated as a subrecipient on federal grants to provide specialized research services.
The Institute For Cancer Research holds a multiple-award Indefinite Delivery Contract from the National Cancer Institute to provide preclinical efficacy and biomarker analysis services in support of the PREVENT Cancer Preclinical Drug Development Program. This 5-year contract encompasses three pools - Preclinical Efficacy and Biomarkers, Preclinical Services for Product Development and Manufacturing, and Preclinical Toxicology and Pharmacology Testing. Task orders under this IDIQ focus on continued evaluation of candidate chemopreventive and immunopreventive regimens.
FF1XVJMDYVR1 541715
Not listed 333 Cottman Ave, Cheltenham, PA 19012, USA
9/11/00 2/6/26 Weill Medical College Of Cornell University
Weill Medical College of Cornell University, doing business as Joan & Sanford I Weill Medical College of Cornell University, is a prestigious private research university focused on biomedical research and medical education. As a leading academic medical center, it provides a wide range of services to the federal government through contract and grant awards, primarily in the areas of medical research, clinical trials, and healthcare innovations. The institution has a strong track record of securing federal funding to advance scientific knowledge and improve patient care across various medical specialties.
Through federal contract awards, Weill Medical College has provided services such as clinical research, data analysis, and development of medical technologies. The institution has worked on projects related to cancer research, infectious diseases, and neurological disorders for agencies like the National Cancer Institute and the Department of Defense. As both a prime contractor and subcontractor, Weill Medical College has collaborated with other research institutions and private companies to deliver complex biomedical research projects. While no specific set-aside designations were mentioned, the college has demonstrated its ability to compete for and win significant federal contracts in the healthcare and research sectors.
Weill Medical College has received numerous federal grant awards to conduct cutting-edge biomedical research and clinical studies. These grants have supported work in areas such as Alzheimer's disease, HIV/AIDS, cardiovascular health, and precision medicine. The institution has received funding from various National Institutes of Health (NIH) institutes, including the National Cancer Institute, National Institute on Aging, and National Heart, Lung, and Blood Institute. Weill Medical College has also participated in large-scale research initiatives like the All of Us Research Program and has collaborated with other academic institutions on multi-site studies. As both a prime recipient and subrecipient, the college has leveraged its expertise to contribute to national research priorities and advance medical knowledge.
Weill Medical College holds a significant Indefinite Delivery Contract (IDC) with the National Cancer Institute to support the PREVENT Cancer Preclinical Drug Development Program. This multiple-award IDC, with a ceiling value of $149,995,000, enables the institution to provide preclinical research services such as efficacy testing, biomarker evaluation, analytical assay development, and Good Manufacturing Practice (GMP) manufacturing to advance cancer preventive agents for clinical trials. The contract is part of a structured approach to transitioning cancer preventive drugs and vaccines from discovery to clinical application. Through this IDV, Weill Medical College can compete for task orders to deliver specialized research services that support the National Cancer Institute's mission to reduce cancer incidence and mortality.
YNT8TCJH8FQ8 611310
Not listed 575 Lexington Ave Fl 9, New York, NY 10022, USA
7/17/01 9/30/25